Sponsored Screening Program

Improving Early Detection of ATTR-CM in Canada

Available to eligible community cardiologists (restrictions apply)

Register Below  ↓


Sponsored Screening

Improving Early Detection of ATTR-CM in Canada

ATTR-CM is a rare but debilitating cardiac condition whose symptoms overlap with more common disorders leading to under- and delayed-diagnosis

This screening program will help improve early detection of ATTR-CM in the community by increasing access to the CA-4F algorithm

About CA-4F

CA-4F is a computational algorithm that estimates the likelihood of equivocal or positive finding for ATTR-CM on Tc-99 m PYP. It is encoded in medical device software deployed at Ensho data labs and applied to the electronic health records of requesting cardiologists as a service. The average community cardiologists can expect CA-4F to predict 20 patients per year to have a >10% probability of  positive findings for ATTR-CM on Tc-99 m PYP. Reports for each patient will be distributed through Compass ↗︎.

About the CA-4F algorithm →

Sample report →

CA-4F Receiver Operating Curve


Cardiologists with a community practice, timely access to Tc-99 m PYP and a compatible EMR system are eligible participate. Compatible EMR systems include:

Contact support@ensho.ai to request a data linkage with an EMR system not listed above.

How to Enroll

Existing Subscribers
New Subscribers



Thank you for your message, someone from our team will be in touch soon.
Something went wrong while submitting the form. Please try again

This sponsored screening program is supported by Pfizer Canada. No patient-identifiable information will be shared with the program sponsor.